Appointment of Allenby Capital as Joint Broker
Updated : 15:21
20 December 2024
BELLUSCURA PLC
("Belluscura" or the "Company")
Appointment of Allenby Capital as Joint Broker
Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, is pleased to announce the appointment of Allenby Capital Limited as the Company's Joint Broker with immediate effect.
For further information please contact:
Belluscura plc | Tel: +44 (0)20 3128 8100 |
Adam Reynolds, Chairman Robert Rauker, CEO Simon Neicheril, Chief Financial Officer
| |
| |
SPARK Advisory Partners Limited Nominated Adviser | Tel: +44 (0)20 3368 3550 |
Neil Baldwin / Jade Bayat | |
Dowgate Capital Limited Joint Broker | Tel: +44 (0)20 3903 7715 |
James Serjeant / Colin Clime (Sales and Corporate Broking) Russell Cook / Nicholas Chambers (Corporate Finance) | |
Allenby Capital Ltd Joint Broker | Tel: +44 (0)20 3328 5656
|
Guy McDougall / Amrit Nahal (Sales and Corporate Broking) Jeremy Porter / Lauren Wright (Corporate Finance) | |
MHP Financial PR & Investor Relations | Tel: +44 (0)20 3128 8100 email: Belluscura@mhpgroup.com |
Katie Hunt/Matthew Taylor |
About Belluscura plc (https://ir.belluscura.com/)
Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.